Evariste
Evariste is an AI-enabled drug discovery company focused on developing small molecule therapeutics that target synthetic lethal pathways in oncology. Their proprietary platform, Frobenius, allows for the identification of novel synthetic lethal targets and biomarkers, enabling tailored treatments for underserved patient populations. Evariste's approach combines automated modeling and machine learning to design high-quality drug candidates efficiently, achieving significant potency increases with minimal compounds tested. The company has established a pipeline of precision oncology therapeutics, including best-in-class inhibitors and first-in-class assets, positioning itself as a leader in the synthetic lethality space with validated projects and collaborations.
Evariste
Evariste is an AI-enabled drug discovery company focused on developing small molecule therapeutics that target synthetic lethal pathways in oncology. Their proprietary platform, Frobenius, allows for the identification of novel synthetic lethal targets and biomarkers, enabling tailored treatments for underserved patient populations. Evariste's approach combines automated modeling and machine learning to design high-quality drug candidates efficiently, achieving significant potency increases with minimal compounds tested. The company has established a pipeline of precision oncology therapeutics, including best-in-class inhibitors and first-in-class assets, positioning itself as a leader in the synthetic lethality space with validated projects and collaborations.